Savara Inc. $SVRA Holdings Increased by Eversept Partners LP

Eversept Partners LP lifted its stake in Savara Inc. (NASDAQ:SVRA) by 125.8% in the first quarter, HoldingsChannel reports. The fund owned 384,264 shares of the company’s stock after purchasing an additional 214,069 shares during the quarter. Eversept Partners LP’s holdings in Savara were worth $2,098,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Rhumbline Advisers raised its holdings in Savara by 10.8% during the second quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock worth $388,000 after purchasing an additional 16,634 shares in the last quarter. Prudential Financial Inc. bought a new position in Savara during the 2nd quarter valued at $30,000. XTX Topco Ltd bought a new position in Savara during the 2nd quarter valued at $201,000. Invesco Ltd. increased its position in shares of Savara by 35.4% during the 2nd quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock valued at $276,000 after purchasing an additional 31,633 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in shares of Savara by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after purchasing an additional 6,449 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on SVRA shares. Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. Finally, Oppenheimer began coverage on Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

Savara Stock Down 1.5%

SVRA stock opened at $5.43 on Tuesday. Savara Inc. has a 12 month low of $2.43 and a 12 month high of $7.01. The firm has a market cap of $1.11 billion, a PE ratio of -9.70 and a beta of 0.24. The firm has a 50 day simple moving average of $5.54 and a 200 day simple moving average of $5.52. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Equities research analysts forecast that Savara Inc. will post -0.57 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.